LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

Search

Crinetics Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

35.48 -0.98

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.98

Massimo

36.36

Metriche Chiave

By Trading Economics

Entrata

7.3M

-123M

Vendite

3.7M

3.9M

EPS

-1.29

Margine di Profitto

-3,161.261

Dipendenti

594

EBITDA

20M

-122M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+144.11% upside

Dividendi

By Dow Jones

Utili prossimi

7 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-586M

3.9B

Apertura precedente

36.46

Chiusura precedente

35.48

Notizie sul Sentiment di mercato

By Acuity

34%

66%

77 / 350 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 mar 2026, 18:34 UTC

Utili

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

19 mar 2026, 17:43 UTC

I principali Market Mover

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

19 mar 2026, 23:47 UTC

Utili

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

19 mar 2026, 23:47 UTC

Utili

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

19 mar 2026, 23:47 UTC

Utili

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

19 mar 2026, 23:47 UTC

Utili

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

19 mar 2026, 23:39 UTC

Utili

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

19 mar 2026, 23:39 UTC

Utili

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

19 mar 2026, 23:39 UTC

Utili

Li Ning: Outdoor Category Continued Growing >2331.HK

19 mar 2026, 23:38 UTC

Utili

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

19 mar 2026, 23:33 UTC

Discorsi di Mercato

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

19 mar 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

19 mar 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

McCormick Has a Market Value of Around $14.8B -- WSJ

19 mar 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

19 mar 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

19 mar 2026, 22:23 UTC

Discorsi di Mercato

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

19 mar 2026, 22:09 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

19 mar 2026, 22:06 UTC

Discorsi di Mercato

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

19 mar 2026, 22:04 UTC

Utili
Acquisizioni, Fusioni, Takeovers

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

19 mar 2026, 22:03 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Energy Roundup: Market Talk

19 mar 2026, 22:03 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

19 mar 2026, 21:51 UTC

Utili
Acquisizioni, Fusioni, Takeovers

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

19 mar 2026, 20:57 UTC

Principali Notizie su Eventi

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

19 mar 2026, 20:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

19 mar 2026, 20:19 UTC

Principali Notizie su Eventi

Brent Crude Retreats After Touching $119 -- WSJ

19 mar 2026, 19:49 UTC

Discorsi di Mercato

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

19 mar 2026, 19:26 UTC

Principali Notizie su Eventi

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

19 mar 2026, 19:10 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Natural Gas Rises in Volatile Trading -- Market Talk

19 mar 2026, 19:06 UTC

Principali Notizie su Eventi

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

19 mar 2026, 18:08 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

144.11% in crescita

Previsioni per 12 mesi

Media 88 USD  144.11%

Alto 97 USD

Basso 67 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

12

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

77 / 350 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat